TIDMSCLP
Scancell Holdings Plc
19 October 2021
Scancell expands its R&D capabilities with new facilities at
The Oxford Science Park
Oxford, UK, 19 October 2021 - Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer
and infectious disease, has expanded its R&D capabilities by
taking new laboratory and office space in the Bellhouse Building at
The Oxford Science Park (TOSP), one of the UK's leading parks for
science and technology companies. The new premises, which are
complementary to Scancell's laboratories in the Biodiscovery
Institute at the University of Nottingham, will allow the Company
to further accelerate the development of its portfolio of
immunotherapies.
Scancell, which raised GBP46 million last year to drive its
pipeline through clinical trials, is now working from 1,900 sq ft
of laboratory space and 1,800 sq ft of office facilities at TOSP.
Scancell currently employs just over 40 staff, of which
approximately half are located in the new premises and plans to
recruit additional people to its clinical and product development
teams in the next 12 months.
The Company is developing novel immunotherapies for the
treatment of cancer based on its technology platforms,
ImmunoBody(R) , Moditope(R) and AvidiMab(TM) , with innovative
products in multiple cancer indications and a vaccine in
development for COVID-19. The new laboratories will support the
Company's clinical trial activities and provide analytical and
formulation facilities for future product development.
Professor Lindy Durrant, Chief Executive Officer, Scancell,
said: "TOSP is the perfect location for Scancell's expansion, with
access to an excellent local talent pool as we grow the business.
We are excited to be part of the creative and collaborative group
of companies located in the Park and look forward to further
developing our innovative products at this new site."
Rory Maw, CEO of TOSP, said: "We are delighted that Scancell has
chosen to locate its new R&D facility at The Oxford Science
Park, the Company's first laboratories outside of the university
setting. Scancell joins Enara Bio, MoA Technology and Sitryx in the
Bellhouse Building. With its leading research in cancer and
infectious disease, the Company is a great addition to the
innovation community here. This is exciting news for TOSP,
following the announcement of our partnership with GIC to
accelerate development of the Park."
-ENDS-
For more information, please contact:
The Oxford Science Park
Emma Palmer Foster
Tel: +44 (0)7880 787185
emmapf@oxfordsp.com
Scancell Holdings plc +44 (0) 20 3727 1000
Dr John Chiplin, Executive Chairman
Professor Lindy Durrant, CEO
Panmure Gordon (UK) Limited (Nominated
Adviser and Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Stifel Nicolaus Europe Limited (Joint
Broker) +44 (0) 20 7710 7600
Nicholas Moore/Samira Essebiyea (Healthcare
Investment Banking)
Nick Adams (Corporate Broking)
FTI Consulting +44 (0) 20 3727 1000
Simon Conway/Natalie Garland-Collins
Notes to Editors
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its technology platforms, ImmunoBody(R) ,
Moditope(R) and AvidiMab(TM) , with four products in multiple
cancer indications and development of a vaccine for COVID-19.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
CD4 and CD8 T cells with the ability to identify, target and
eliminate cancer cells. These cancer vaccines have the potential to
be used as monotherapy or in combination with checkpoint inhibitors
and other agents. The Directors believe that this platform has the
potential to enhance tumour destruction, prevent disease recurrence
and extend survival.
DNA vaccine against COVID-19: As research data emerges, it is
becoming increasingly clear that the induction of potent and
activated T cells may play a critical role in the development of
long-term immunity and clearance of virus-infected cells. Initial
research is underway and Scancell has initiated a Phase 1 clinical
trial known as COVIDITY in October 2021.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress induced
post-translational modifications (siPTMs). Examples of such
modifications are citrullination, an enzyme-based conversion of
arginine to citrulline, and homocitrullination (or carbamylation),
in which lysine residues are converted to homocitrulline.
Expression of peptides containing these modifications have been
demonstrated to induce potent CD4 cytotoxic T cells to eliminate
cancer. The Directors believe that this platform has the potential
to eradicate hard to treat solid tumours.
AvidiMab(TM) has broad potential to increase the avidity or
potency of any therapeutic monoclonal antibody (mAb) including
those being developed for autoimmune diseases, as well as cancer.
Scancell's development pipeline includes mAbs against specific
tumour-associated glycans (TaGs) with superior affinity and
selectivity profiles, that have now been further engineered using
the Company's AvidiMab(TM) technology; this confers the Scancell
anti-TaG mAbs with the ability to directly kill tumour cells. The
mAbs targeting TaGs can also be used to deliver cytotoxic payload
to cancer or to redirect T cells. The Company has entered into
three non-exclusive research agreements with leading antibody
technology companies to evaluate the Company's anti-TaG mAbs
including those enhanced with the AvidiMab(TM) technology.
About The Oxford Science Park
The Oxford Science Park (TOSP) is majority owned and fully
managed by Magdalen College, Oxford. It recently entered into a
strategic partnership with global long-term investor GIC to
accelerate development of the Park. Created in 1991, TOSP upholds
the College's heritage and provides one of the most influential
science & technology environments in the UK. There is high
quality workspace accommodation across the Park, which is now home
to 2,700 people and more than 130 businesses. These range from
start-ups based in the Magdalen Centre innovation hub to major
international companies, including Blue Earth Diagnostics, MiroBio,
OrganOx, OxSonics Therapeutics, Oxford Nanopore Technologies,
OXGENE, ProImmune, Evox Therapeutics, Vaccitech, Exscientia,
Sensyne Health and Intuitive Surgical.
In addition to being a key property investment, the Park is at
the heart of Magdalen College's strategy to support discovery,
innovation and entrepreneurship. The Oxford Science Park will
continue to be developed as a long-term strategic asset. Additional
capacity will support the growth of businesses already based on the
Park, providing flexible workspace accommodation, and enabling new
companies to enjoy the Park's exceptional environment and
collegiate and collaborative ethos.
The Oxford Science Park is located approximately four miles
south-east of Oxford city centre, just off the City's southern ring
road. It has easy access to the M40 and A34, as well as to Heathrow
Airport and mainline train services. For further information,
please visit: www.oxfordsp.com or follow us on twitter
@OxfordSciencePK
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFIDIDLTLIL
(END) Dow Jones Newswires
October 19, 2021 02:00 ET (06:00 GMT)
Scancell (LSE:SCLP)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Scancell (LSE:SCLP)
Gráfica de Acción Histórica
De May 2023 a May 2024